sorafenib has been researched along with zonisamide in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (zonisamide) | Trials (zonisamide) | Recent Studies (post-2010) (zonisamide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 922 | 121 | 382 |
| Protein | Taxonomy | sorafenib (IC50) | zonisamide (IC50) |
|---|---|---|---|
| Carbonic anhydrase 12 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 2 | Bos taurus (cattle) | 1.86 | |
| Carbonic anhydrase 3 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 4 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 6 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 7 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 13 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 14 | Homo sapiens (human) | 1.86 | |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | 1.86 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for sorafenib and zonisamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sorafenib and zonisamide
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |